Revelation Biosciences is developing innovative solutions for Acute Kidney Injury (AKI), targeting a potential $94 billion market with its Stage 2 and Stage 3 treatments.
1 report, 1 independent
Updated Aug 3
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Revelation Biosciences is developing innovative solutions for Acute Kidney Injury (AKI), targeting a potential $94 billion market with its Stage 2 and Stage 3 treatments.
How it developed
Newest first. Tap a step to see who reported it.- A clinical study evaluating the Gemini program in the context of acute kidney injury began on June 30.Sub-event
- Market assessment showed $94B TAM for Gemini.Sub-event
Revelation Biosciences targets the $94B AKI market with innovative solutions for Stage 2 and Stage 3 disease.1 source